A citation-based method for searching scientific literature

Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F Nelson, Grant McArthur, Jeffrey A Sosman, Antoni Ribas, Roger S Lo. Nature 2010
Times Cited: 1519







List of co-cited articles
906 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
31

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Cory M Johannessen, Jesse S Boehm, So Young Kim, Sapana R Thomas, Leslie Wardwell, Laura A Johnson, Caroline M Emery, Nicolas Stransky, Alexandria P Cogdill, Jordi Barretina,[...]. Nature 2010
31

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva, Adina Vultur, John T Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A Gimotty, Damien Kee,[...]. Cancer Cell 2010
906
29

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay,[...]. Nature 2011
986
28

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
26

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B Johnson, Kimberly B Dahlman,[...]. Cancer Discov 2014
630
25


Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T Flaherty, Igor Puzanov, Kevin B Kim, Antoni Ribas, Grant A McArthur, Jeffrey A Sosman, Peter J O'Dwyer, Richard J Lee, Joseph F Grippo, Keith Nolop,[...]. N Engl J Med 2010
21

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Chong Sun, Liqin Wang, Sidong Huang, Guus J J E Heynen, Anirudh Prahallad, Caroline Robert, John Haanen, Christian Blank, Jelle Wesseling, Stefan M Willems,[...]. Nature 2014
494
20

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, Daniel J Treacy, Cory M Johannessen, Eva M Goetz, Chelsea S Place, Amaro Taylor-Weiner, Steven Whittaker, Gregory V Kryukov,[...]. Cancer Discov 2014
573
18

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Hubing Shi, Gatien Moriceau, Xiangju Kong, Mi-Kyung Lee, Hane Lee, Richard C Koya, Charles Ng, Thinle Chodon, Richard A Scolyer, Kimberly B Dahlman,[...]. Nat Commun 2012
460
18

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Nikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, Dennie T Frederick, Zachary A Cooper, Amaro Taylor-Weiner, Mara Rosenberg, Eva M Goetz, Ryan J Sullivan, Deborah N Farlow,[...]. Cancer Discov 2014
321
17

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Ravid Straussman, Teppei Morikawa, Kevin Shee, Michal Barzily-Rokni, Zhi Rong Qian, Jinyan Du, Ashli Davis, Margaret M Mongare, Joshua Gould, Dennie T Frederick,[...]. Nature 2012
17

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
Nikhil Wagle, Caroline Emery, Michael F Berger, Matthew J Davis, Allison Sawyer, Panisa Pochanard, Sarah M Kehoe, Cory M Johannessen, Laura E Macconaill, William C Hahn,[...]. J Clin Oncol 2011
683
17

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim,[...]. N Engl J Med 2012
17

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Gatien Moriceau, Willy Hugo, Aayoung Hong, Hubing Shi, Xiangju Kong, Clarissa C Yu, Richard C Koya, Ahmed A Samatar, Negar Khanlou, Jonathan Braun,[...]. Cancer Cell 2015
201
17

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Willy Hugo, Hubing Shi, Lu Sun, Marco Piva, Chunying Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B Dahlman, Douglas B Johnson,[...]. Cell 2015
327
16

MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Caroline M Emery, Krishna G Vijayendran, Marie C Zipser, Allison M Sawyer, Lili Niu, Jessica J Kim, Charles Hatton, Rajiv Chopra, Patrick A Oberholzer, Maria B Karpova,[...]. Proc Natl Acad Sci U S A 2009
453
16

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
15

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
15

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
15

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.
Helen Rizos, Alexander M Menzies, Gulietta M Pupo, Matteo S Carlino, Carina Fung, Jessica Hyman, Lauren E Haydu, Branka Mijatov, Therese M Becker, Suzanah C Boyd,[...]. Clin Cancer Res 2014
311
15

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
14

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Georgina V Long, Carina Fung, Alexander M Menzies, Gulietta M Pupo, Matteo S Carlino, Jessica Hyman, Hamideh Shahheydari, Varsha Tembe, John F Thompson, Robyn P Saw,[...]. Nat Commun 2014
197
14

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, Rene Gonzalez, Anna C Pavlick, Jeffrey S Weber, Grant A McArthur, Thomas E Hutson, Stergios J Moschos, Keith T Flaherty,[...]. N Engl J Med 2012
14

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Lancet Oncol 2016
471
13

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
334
13

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
12

Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, Sara Aibar, Julia Femel, Michael Dewaele, Panagiotis Karras, Daniel Brown, Young Hwan Chang, Maria Debiec-Rychter,[...]. Cell 2018
181
12

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev V Demidov, Jessica C Hassel, Piotr Rutkowski, Peter Mohr,[...]. N Engl J Med 2012
12

A landscape of driver mutations in melanoma.
Eran Hodis, Ian R Watson, Gregory V Kryukov, Stefan T Arold, Marcin Imielinski, Jean-Philippe Theurillat, Elizabeth Nickerson, Daniel Auclair, Liren Li, Chelsea Place,[...]. Cell 2012
12

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
Steven R Whittaker, Jean-Philippe Theurillat, Eliezer Van Allen, Nikhil Wagle, Jessica Hsiao, Glenn S Cowley, Dirk Schadendorf, David E Root, Levi A Garraway. Cancer Discov 2013
225
12

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Judith Müller, Oscar Krijgsman, Jennifer Tsoi, Lidia Robert, Willy Hugo, Chunying Song, Xiangju Kong, Patricia A Possik, Paulien D M Cornelissen-Steijger, Marnix H Geukes Foppen,[...]. Nat Commun 2014
312
12

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Dennie T Frederick, Adriano Piris, Alexandria P Cogdill, Zachary A Cooper, Cecilia Lezcano, Cristina R Ferrone, Devarati Mitra, Andrea Boni, Lindsay P Newton, Chengwen Liu,[...]. Clin Cancer Res 2013
614
11

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets,[...]. Nature 2010
11

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Sydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, Eduardo A Torre, Benjamin Emert, Clemens Krepler, Marilda Beqiri, Katrin Sproesser, Patricia A Brafford, Min Xiao,[...]. Nature 2017
416
11

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Mohammad Fallahi-Sichani, Verena Becker, Benjamin Izar, Gregory J Baker, Jia-Ren Lin, Sarah A Boswell, Parin Shah, Asaf Rotem, Levi A Garraway, Peter K Sorger. Mol Syst Biol 2017
107
11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
215
11

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Itay Tirosh, Benjamin Izar, Sanjay M Prakadan, Marc H Wadsworth, Daniel Treacy, John J Trombetta, Asaf Rotem, Christopher Rodman, Christine Lian, George Murphy,[...]. Science 2016
11

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly,[...]. N Engl J Med 2016
11

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob,[...]. Lancet 2015
771
10

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
Matthew Holderfield, Marian M Deuker, Frank McCormick, Martin McMahon. Nat Rev Cancer 2014
444
10

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
10

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Piro Lito, Christine A Pratilas, Eric W Joseph, Madhavi Tadi, Ensar Halilovic, Matthew Zubrowski, Alan Huang, Wai Lin Wong, Margaret K Callahan, Taha Merghoub,[...]. Cancer Cell 2012
343
10

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
David J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, Jong Wook Kim, Zachary A Cooper, Adriano Piris, Dennie T Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq,[...]. Cancer Discov 2014
288
10

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
Douglas B Johnson, Alexander M Menzies, Lisa Zimmer, Zeynep Eroglu, Fei Ye, Shilin Zhao, Helen Rizos, Antje Sucker, Richard A Scolyer, Ralf Gutzmer,[...]. Eur J Cancer 2015
165
10

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Sonja J Heidorn, Carla Milagre, Steven Whittaker, Arnaud Nourry, Ion Niculescu-Duvas, Nathalie Dhomen, Jahan Hussain, Jorge S Reis-Filho, Caroline J Springer, Catrin Pritchard,[...]. Cell 2010
10

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
10

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A Sosman, Vicki Keedy, Manish R Patel, Geoffrey I Shapiro, James W Mier, Anthony W Tolcher,[...]. Cancer Discov 2018
150
9

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
326
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.